Axatilimab (Niktimvo) for Chronic Graft-Versus-Host Disease (online only)
Axatilimab (Niktimvo) for Chronic Graft-Versus-Host Disease (online only)
November 11, 2024 (Issue: 1715)
Axatilimab-csfr (Niktimvo – Incyte), a colony
stimulating factor-1 receptor-blocking antibody, has
been approved by the FDA for intravenous treatment
of chronic graft-versus-host disease (cGVHD) after
failure of at least 2 lines of systemic...more
- F Malard and M Mohty. Updates in chronic graft-versus-host disease management. Am J Hematol 2023; 98:1637. doi:10.1002/ajh.27040
- M Mohty. CSF1R blockade for refractory chronic graft-versus-host disease. N Engl J Med 2024; 391:1055. doi:10.1056/nejme2407369
- D Wolff et al. Axatilimab in reurrent or refractory chronic graft-versus-host disease. N Engl J Med 2024; 391:1002. doi:10.1056/ nejmoa2401537
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Axatilimab (Niktimvo) for Chronic Graft-Versus-Host Disease (online only)
Article code: 1715e
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
